A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Clinical trial NCT05661955 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05661955
Sponsor: BeiGene
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma Renal Cell Carcinoma Melanoma Non-mucosal Melanoma

Start date: 2023-01-09
Primary completion: 2025-05-27
Enrollment: 113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.